May 13, 2020 05:02 PM EDTUpdated 05:24 PM
R&D

Macro­Gen­ics chief Scott Koenig de­tails the up­beat can­cer drug da­ta from 2 pro­grams that drove a big spike in their share price

John Carroll

Editor & Founder

Macro­Gen­ics $MGNX dropped their AS­CO ab­stracts on 2 key drug pro­grams on Wednes­day evening, high­light­ing some ad­di­tion­al de­tails on da­ta that spurred their share …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times